+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Uveal Melanoma Pipeline Analysis and Outlook, 2019

  • ID: 4772465
  • Report
  • May 2019
  • Region: Global
  • 112 pages
  • VPA Research


  • AstraZeneca Plc
  • Castle Biosciences Inc
  • Exelixis Inc
  • IDEAYA Biosciences Inc
  • Novartis AG
  • Plexxikon Inc
  • MORE
Uveal Melanoma pipeline

Uveal Melanoma pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Uveal Melanoma R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Uveal Melanoma report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Uveal Melanoma as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Uveal Melanoma with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Uveal Melanoma pipeline Profiled in detail

Key players actively participating in Uveal Melanoma pipeline are profiled along with their R&D progress in Uveal Melanoma treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Uveal Melanoma pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Uveal Melanoma treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Uveal Melanoma pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Uveal Melanoma pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Uveal Melanoma pipeline study
  • All recent news and developments related to Uveal Melanoma drugs are provided
Note: Product cover images may vary from those shown


  • AstraZeneca Plc
  • Castle Biosciences Inc
  • Exelixis Inc
  • IDEAYA Biosciences Inc
  • Novartis AG
  • Plexxikon Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Uveal Melanoma Disease Overview

3. Uveal Melanoma Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Uveal Melanoma Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Uveal Melanoma Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Uveal Melanoma companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Uveal Melanoma Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • Aeglea BioTherapeutics Inc
  • AstraZeneca Plc
  • Aura Biosciences Inc
  • Bellicum Pharmaceuticals Inc
  • BioMed Valley Discoveries Inc
  • Bristol-Myers Squibb Co
  • Castle Biosciences Inc
  • Delcath Systems Inc
  • Eli Lilly and Co
  • Exelixis Inc
  • Harmonic Pharma
  • Iconic Therapeutics Inc
  • IDEAYA Biosciences Inc
  • Immunocore Ltd
  • Inventiva
  • Iovance Biotherapeutics Inc
  • Novartis AG
  • PEP-Therapy
  • Pfizer Inc
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Tesaro Inc
  • Viralytics Ltd
Note: Product cover images may vary from those shown